Gilde Healthcare has raised 517 million EUR towards the first and final close of Gilde Healthcare Private Equity IV (GHPE IV).

GHPE IV focuses on investments in profitable healthcare companies operating in the lower mid-market in North-west Europe. The fund concentrates on firms with an active buy-and-build strategy and invests in all sub-segments of the healthcare sector. These include companies in healthcare provision, service providers to the healthcare sector and medical industry, manufacturers of medical supplies and pharmaceutical companies.

Read more: Gilde Healthcare acquires majority stake in KLIFO

“With the new fund, we will expand our portfolio with differentiating European growth platforms in the healthcare sector. With our active investment strategy, we are responding to the market’s need for increasing scale, quality improvement and efficiency. Furthermore, our pipeline comprises several attractive new investments in North-west Europe,” says Jasper van Gorp, Managing Partner at Gilde Healthcare and Head of the Private Equity team.

Read more: Interview: Rafael Natanek, Gilde Healthcare Private Equity

Attracting investors from Scandinavia

Market interest was strong and the new fund was oversubscribed, attracting institutional investors from the Netherlands, Germany, United Kingdom, France, Italy, and Scandinavia.

“We are proud of the strong interest in our funds. Increasingly, institutional investors such as pension funds are looking for impactful investments in healthcare. With our investment strategy focused on high-quality and affordable healthcare, we not only realize attractive returns, but we also offer participants the opportunity to invest in companies that enhance the efficiency and accessibility of healthcare,” says Pieter van der Meer, co-Founder and Managing Partner at Gilde Healthcare, responsible for fundraising.

Gilde Healthcare has two fund strategies under management, focused on the healthcare sector: Private Equity and Venture&Growth. Gilde Healthcare has raised 933 million EUR in two years for its private equity and transatlantic venture&growth funds

Photo: iStock